PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20180131 184159
20170801 230809
20180815 142243
DJI 0012
DJI 0041
20180130 153213
  • Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 26, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Zarzio, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Voydeya, danicopan, Date of authorisation: 19/04/2024, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Date of authorisation: 08/02/2018, Revision: 16, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Obgemsa, vibegron, Date of authorisation: 27/06/2024, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Holoclar, ex vivo expanded autologous human corneal epithelial cells containing stem cells, Date of authorisation: 17/02/2015, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Human medicines European public assessment report (EPAR): Erleada, apalutamide, Date of authorisation: 14/01/2019, Revision: 17, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-08
  • Biosimilars Research: Awards
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • FDA Public Meeting: BsUFA III Regulatory Science Program Interim Public Meeting - 09/18/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • What's New Related to Drugs
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Drug Trials Snapshot: ROMVIMZA
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Endothelin Receptor Antagonist REMS Information
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • CDER Manual of Policies & Procedures | MAPP
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
  • Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-07 By FDA
Older posts
Theme: Scaffold by Danny Cooper.